Kornimate/medical-research-clean huggingface dataset:
scintigraphic defecography for evaluation of functional outcome in an adult hirschsprung population

Conditions: Hirschsprung Disease

Summary: this study aims to investigate long term outcomes of surgical intervention for hirschsprung's disease and to explore the relation between scintigraphic defecography, type of surgery performed and symptoms as evaluated by a disease specific questionnaire.

hirschsprung's disease (hd) is a congenital deficiency with incomplete development of nerves in the gastrointestinal tract leading to absence of peristalsis in the affected segment of bowel. most patients require surgical intervention with removal of the affected segment of bowel. physical symptoms affecting quality of life are not uncommon in patients born with hd in spite of surgical intervention. this renders a need for a tool for evaluating the functional outcome in these patients. scintigraphic defecography examines the defecation in terms of the ability to empty the bowel and examines the relocation of faeces within the bowel in relation to defecation. this study aims to explore the relation between scintigraphic defecography, type of surgery performed and symptoms as evaluated by a disease specific questionnaire (hirschsprung and anorectal malformations quality of life questionnaire).

Eligibility criteria:
inclusion criteria: * patients operated with any type of surgery for hirschsprung's disease between 1985-2014 * age \> 15 years exclusion criteria: * unable to understand given instructions in relation to the defecography (ex. retarded) * pregnancy * missing consent

Keywords: hirschsprung disease scintigraphic defecography
behavioural problems in huntington disease : analysis and enhancement of caregiver and patient experience

Conditions: Huntington Disease

Summary: the study hypothesis is that caregivers experience allows them to develop a lot of knowledge and know-how about behavioural problems in huntington disease and its consequences. the purpose of this study is to collect, describe and analyse caregivers experience in order to find and enhance their knowledge related to the adaptation to behavioural problems of huntington disease patients.


Eligibility criteria:
inclusion criteria: * for patients: * patients with huntington disease declared * huntington disease diagnosed with abnormal number of cag repeats: 38 \< nucleotide expansion (cag) * total functional capacity ≥ 7 * patients living with a caregiver * aged 18 years and above * subject gave its written consent * for caregivers : * no risk of caregiver having huntington disease * aged 18 years and above * subject gave its written consent exclusion criteria: * for patients: * patient who do not live with a caregiver * no national health insurance affiliation * being under guardianship * for caregivers : * caregiver at risk for huntington disease * no national health insurance affiliation * being under guardianship
sensory integration therapy training in patients with lumbar spinal stenosis

Conditions: Lumbar Spinal Stenosis

Summary: lumbar spinal stenosis is a common degenerative disease in the elderly. patients are often accompanied by paresthesias and decreased musculoskeletal system functions, resulting in disability and increasing the burden of medical care. the balance and walking ability of such patients are affected by the compressed nerves, so it is necessary to reorganize the nerve sensory systems to compensate for the disability caused by lumbar stenosis. it is necessary to strengthen the training of sensory integration ability, but it has not been studies have investigated which treatments or surgery can improve sensory integration in patients with lumbar stenosis. therefore, this study will develop a clinical tool to objectively evaluate sensory integration, quantify the sensory integration ability of patients with lumbar stenosis and neurological claudication; the influence and mechanism of the balance ability.

objective 1. to develop a sensory integration assessment tool for patients with lumbar stenosis, in order to explore the distribution ratio of sensory system weights between them and healthy elders of the same age without lumbar stenosis under different balance disturbance stimuli. objective 2. to explore the distribution ratio of sensory system weights and long-term tracking of changes in sensory system weights in patients with lumbar stenosis and neurological claudication who received sensory integration training after spinal decompression surgery.

Eligibility criteria:
inclusion criteria: 1. age between 50 and 79 years old 2. patients with lumbar stenosis and neurological claudication diagnosed according to mri 3. timed sit-stand-walk test greater than 9 seconds 4. can stand independently for more than 30 seconds exclusion criteria: 1. previous lumbar surgery 2. neurological disorder such as stroke or spinal cord injury 3. metabolic disease such as diabetes mellitus 4. vestibular disease such as meniere's disease.

Keywords: lumbar spinal stenosis functional assessment center of pressure balance ability
possible relation of toll-like receptors and nitric oxide to chronic lung disease

Conditions: Lung Diseases

Summary: the first objective of this study is to determine if increased expression of one or more members of the toll-like receptor (tlr) family of receptors that are found on inflammatory cells (present in the airway) precede development of chronic lung disease (cld) of prematurity. the study will also determine if there is a significant correlation between tlrs and the severity of cld. the second objective of this study is to determine the impact of c-administration of inhaled nitric oxide (ino) on tlr expression in infants at risk of developing cld or with early cld.

background: this study will examine the role of two members in the family of transmembrane receptors, tlrs, found on leukocytes and other cells that are upregulated in response to endotoxin and other stimuli. these substances transfer the signals that propagate inflammation and production of inflammatory cytokines. cld of prematurity is characterized by early (first week of life) evidence of lung airway inflammation. it is unknown if tlr family members propagate this pathway. design narrative: this study will involve saving weekly tracheal aspirate fluid samples obtained with routine airway toilet in infants less than or equal to 1250 gm birth weight, who are admitted to a neonatal intensive care unit requiring assisted ventilation via an endotracheal tube. the waste sample will be collected with the cellular contents separated by centrifugation and placed on trizol reagent after obtaining a cell count. later extraction and batch analysis of tlr, mrna, and proteins as well as mrna and protein for housekeeping genes will be performed. immunohistochemistry will also be used to semi-quantitate the samples. samples will be obtained in the first one to two days, and again at the end of the first week of life. in infants who were also participating in the related "low dose ino in cld of prematurity" study, in which tracheal aspirate samples were collected, when the code is broken to determine who received nitric oxide versus placebo, the second aim of the study will be carried out: to determine the impact, if any, of ino.

Eligibility criteria:
inclusion criteria: * birth weight less than 1250 gm * requiring assisted ventilation exclusion criteria: * moribund condition * major pulmonary or cardiovascular associated anomaly
the efficacy study of the evidence-based psychological intervention for improving resilience and preventing burnout of residents

Conditions: Burn Out (Psychology)

Summary: there are few systematic studies on the working environment and mental health of residents who are at the forefront of korean medical care. in particular, there is no scientific research on burnout prevention. since preventing burnout of surgical residents is directly related not only to personal well-being but the health of the patients, it is necessary to care for the individual's psychological state at a social level. this psychological intervention program that is expected to improve recovery resilience in stressful situations of residents and prevent burnout is implemented, and its effectiveness is to be verified.


Eligibility criteria:
inclusion criteria: * surgical trainees (residents and clinical fellows) at bundang seoul national university hospital, who is 20 years of age or older, regardless of sex or race. exclusion criteria: * subjects who do not consent to the study * subjects with meditation experience

Keywords: resident surgery ego resilience mindfulness
bergamot and cardio-metabolic risk factors

Conditions: Dyslipidemia

Summary: bergamot-derived products have shown significant effects on plasma lipids. we aim in the present study to evaluate the effect of bergamot on several cardio-metabolic risk markers.

the research hypothesis is to assess whether bergamot reduces plasma lipids (total cholesterol, triglycerides, low-density lipoprotein (ldl)-cholesterol and high-density lipoprotein (hdl)-cholesterol), atherogenic lipoproteins, carotid intima-media thickness (imt) and liver steatosis in patients with dyslipidemia. the primary objective is to assess whether bergamot reduces plasma lipids and atherogenic lipoproteins in patients with dyslipidemia. primary endpoint: reduction in plasma lipids and atherogenic lipoproteins. the secondary objective is to assess whether bergamot reduces carotid intima-media thickness (imt) and liver steatosis in patients with dyslipidemia. secondary endpoint: reduction in imt and and liver steatosis. clinical diagnostic tools will include the measurement of: 1. cimt, that will be assessed by b-mode real-time ultrasound using a single sonographer (medison sonoace pico, with a probe of 7.5-10.0 mhz) in a standardized manner with fixed angles of insonation; 2. liver steatosis, that will be assessed by by abdominal ultrasound. biochemical analyses will include the analysis of: 1. routine testing of plasma lipids; 2. atherogenic lipoproteins, e.g. the analysis of 11 distinct lipoproteins including very-low-density lipoprotein (vldl), 3 intermediate density lipoprotein (idl) subclasses and 7 low density lipoprotein (ldl) subclasses.

Eligibility criteria:
inclusion criteria: * elevated ldl-cholesterolemia exclusion criteria: * severe hepatic or renal diseases
atorvastatin therapy on xanthoma in alagille syndrome

Conditions: Alagille Syndrome; Atorvastatin; Xanthoma

Summary: to observe the efficacy and safety of atorvastatin on xanthoma in alagille syndrome through a prospective study.

alagille syndrome (algs, omim 118450) is an important cause of chronic cholestasis in children, and the incidence rate is about 1:30000\~1:50000. most patients with algs have hypercholesterolemia. in severe cases, multiple xanthomas can be seen, and some patients are accompanied by severe itching and pain. disfigured xanthomas affect the normal social interaction of patients, thereby causing physical and mental damage to children. at present, xanthoma caused by hypercholesterolemia can be cured by treating the primary disease, taking lipid-lowering drugs (such as bile acid chelators, ezetimibe, statins, etc.), or lipoprotein apheresis. if it affects the beauty or function, local treatment such as 33% trichloroacetic acid dot coating, carbon dioxide laser, liquid nitrogen freezing or surgical resection is feasible, and even surgical operation( such as portal vena cava anastomosis, liver transplantation). compared with expensive lipoprotein apheresis and other invasive therapies, taking lipid-lowering drug has the advantages of higher acceptance, lower cost and higher safety. however, at present, there are no guidelines for application of oral lipid-lowering drugs in children under 6 years old with hypercholesterolemia. therefore, the purpose of this study is to clarify the safety and efficacy of atorvastatin on xanthoma in algs , so as to provide reference for the treatment of algs patients' xanthomas. risk prevention and treatment: the patients began to take atorvastatin from a small dose, followed up closely in the early stage (2-4 weeks) to see if the patients had obvious discomfort such as myalgia, and monitored the changes of biochemistry (ck, alt, ast, etc.). if moderate or more serious adverse reactions occurred during the trial or the following laboratory abnormalities occurred (ck exceeded 10 times the upper limit of normal; alt or ast had been continued to rise, exceeding 2 times the baseline value), atorvastatin was temporarily stopped, and patients should be rechecked within 2 weeks. it is necessary to reevaluate and decide whether to restart atorvastatin treatment.

Eligibility criteria:
inclusion criteria: * meet the algs diagnostic criteria; * xanthoma of skin; * before treatment with atorvastatin,non-hdl-c≥5.76mmol/l（223 mg/dl）; * informed consent; * age 0-17 years old, male or female; * taking bile acid chelator (colenemide) has no obvious effect or intolerance. exclusion criteria: * liver transplantation has been performed; * in the recovery period of cholestasis, xanthoma is obviously subsiding; * patients with serious systemic diseases and unstable vital signs; * progressive active liver injury, such as continuous increase of transaminase; * serious myopathy; * known to be allergic to any component of atorvastatin; * the weight is less than 5kg.
prasugrel versus double dose clopidogrel to treat clopidogrel low-responsiveness after pci

Conditions: Coronary Artery Disease; Percutaneous Coronary Intervention; Acute Coronary Syndromes

Summary: all patients undergoing elective or sub-acute pci are screened by multiplate test for clopidogrel low-responsiveness after receiving 600 mg clopidogrel the day before. a cut off value has previously been established. only low-responders with multiplate values above the cut off value are included in the study. the patients are randomized to either clopidogrel 150 mg once daily or prasugrel 10 mg (age \> 75 og bodyweight \< 60 kg 5 mg)once daily for 30 days after the procedure. follow up will be at 30 days after pci were another multiplate test will be performed. primary endpoint:platelet inhibition (by multiplate) after 30 days of intensified antiplatelet therapy. clinical endpoints such as bleeding complications (gusto, timi) during treatment, and major adverse cardiac events (mace) at 30 days will be collected and reported but the study size does not allow for formal statistical analysis the study ends by the 30 days follow up visit and all patients continue with clopidogrel 75 mg once daily for another 11 months (not study related)


Eligibility criteria:
inclusion criteria: * pci with stenting and multiplate hep-adp \> 70 u despite clopidogrel loading exclusion criteria: * need for vit k antagonist * women with childbearing potential * breastfeeding women * planned surgery within 6 months * intolerance to clopidogrel, prasugrel or aspirin * previous stroke

Keywords: clopidogrel prasugrel low responder multiplate verify now
lethargic depression study

Conditions: Epilepsy; Major Depressive Disorder (MDD)

Summary: this is a study of major depressive disorder (mdd) in patients with decreased energy, pleasure and interests.

a multicenter, double-blind, placebo-controlled comparison of the efficacy and safety of flexible dose extended-release bupropion (hcl) 300-450 mg/day and placebo administered for eight weeks for the treatment of adult outpatients with major depressive disorder including symptoms of decreased energy, pleasure, and interest

Eligibility criteria:
inclusion criteria: * primary diagnosis of mdd with current duration lasting 12 weeks but no greater than 2 years. * generally in good health. * subject must read and write at a level sufficient to provide written informed consent. exclusion criteria: * current or past history of seizure disorder. * subject has a primary diagnosis or received treatment for panic disorder, obsessive compulsive disorder (ocd), post traumatic stress disorder (ptsd), acute stress disorder, bipolar i or ii disorder, schizophrenia, or other psychotic disorder. * currently using illicit drugs or other psychotropic drugs. * patient poses a current suicidal risk or has attempted suicide in the past 6 months.

Keywords: lethargic decreased interest decreased motivation depression
maekmoondong-tang on post-operative cough in patients with lung cancer

Conditions: Postoperative Cough; Lung Cancer

Summary: the aim of the present study is to evaluate the efficacy and safety of maekmoondong-tang on post-operative cough in patients with lung cancer. a randomized, double-blind, placebo-controlled trial will be conducted.


Eligibility criteria:
inclusion criteria: * adults over 20 years old. * patients undergone segmentectomy or lobectomy for lung cancer within 1 month * patients who do not or poorly respond to one week administration of common antitussive agents. * eastern cooperative oncology group(ecog) 0 to 2 * participant is willing and able to give informed consent for participation in the study exclusion criteria: * patients undergoing adjuvant chemotherapy. * patients who have been diagnosed with acute respiratory disease within 1 month. * patients who have been diagnosed with bronchial asthma or bronchiectasis within 1 year * patients taking angiotensin converting enzyme inhibitor * patients with pseudoaldosteronism. * participants who have known prior hypersensitivity to any investigational product component * patient with acute or chronic infections requiring treatment (active hav, hbv, hcv, hiv, tb) * pregnant or lactating females * women of childbearing potential * patient who do not agrees to use effective means of contraception and not to donate sperm during the trial and up to 1 month after final administration * patient who participated other clinical trials of medicine or medical devices within 1 month * individuals who are judged inappropriate for the study by investigator

Keywords: maekmoondong-tang mai-men-dong-tang bakumondo-to
efficacy and safety of regn3500 monotherapy and combination of regn3500 plus dupilumab in adult patients with moderate-to-severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the primary objective of the study is to evaluate the efficacy of regn3500 monotherapy compared with placebo treatment in adult patients with moderate-to-severe atopic dermatitis (ad). secondary objectives are to: * evaluate the efficacy of regn3500 in combination with dupilumab compared with placebo treatment in adult patients with moderate-to-severe ad * assess the safety, tolerability, and immunogenicity of subcutaneous (sc) doses of regn3500 monotherapy and regn3500 in combination with dupilumab in adult patients with moderate-to-severe ad * evaluate the pharmacokinetic (pk) of regn3500 monotherapy and regn3500 in combination with dupilumab in adult patients with moderate-to-severe ad


Eligibility criteria:
key inclusion criteria: 1. chronic ad, according to american academy of dermatology consensus criteria (eichenfield, 2014), that has been present for at least 3 years before the screening visit 2. eczema area and severity index (easi) score ≥16 at the screening and baseline visits 3. ≥10% body surface area (bsa) of ad involvement at the screening and baseline visits 4. documented recent history (within 6 months before the screening visit) of inadequate response to topical ad medication(s) or for whom topical treatments are medically inadvisable key exclusion criteria: 1. prior participation in an anti-interleukin (il)-33 class antibody (including but not limited to regn3500) or anti-il-4rα class antibody (including but not limited to dupilumab) clinical study; past treatment with or current treatment with dupilumab or another anti-il-4rα treatment 2. active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals 2 weeks before the baseline visit, or superficial skin infections within 1 week before the baseline visit 3. known or suspected history of immunosuppression, including history of invasive opportunistic infections (eg, tuberculosis (tb), histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution: or unusually frequent, recurrent, or prolonged infections, per investigator judgment 4. history of human immunodeficiency virus (hiv) infection or positive hiv serology at screening 5. positive with hepatitis b surface antigen (hbsag), hepatitis b core antibody (hbcab), or hepatitis c virus antibody (hcv ab) at the screening visit 6. pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study note: other protocol defined inclusion/exclusion criteria apply

Keywords: moderate severe
the effect of auricular point stimulation on obese women

Conditions: Obesity

Summary: the aim of the study is to examine whether the ear acupoint stimulation is effective on obese women.

% change body weight, bmi, lipid profile, glucose and obese hormone.

Eligibility criteria:
inclusion criteria: * age 16-65 years women * bmi\>27 kg/mm * signed informed consent exclusion criteria: * endocrine disease, e.g. thyroid disorder, pituitary disorder, and sex gland disorder. * heart disease, e.g. arrhythmia, heart failure, myocardial infarction, and patient with pacemaker. * allergy and immunology disease. * high aminotransferases ( alanine, aspartate \> 80 iu/l) or high serum creatinine (\> 2.5 mg/dl) * pregnant or lactating women. * childbirth within 6 months. * stroke or otherwise unable to exercise * management for weight control within 3 months. * any other conditions deemed unsuitable for trial as evaluated by the physician-in-charge. * endocrine disease

Keywords: ear acupuncture obese obese women women
quantitative nodal burden as a determinant identifying ampullary adenocarcinoma patients benefiting from adjuvant chemotherapy

Conditions: Ampullary Adenoma; Chemotherapy Effect

Summary: ampullary cancer, a rare malignancy, lacks standardized guidelines for effective multimodal treatment following curative resection. the opinions on whether postoperative chemotherapy can improve the long-term survival of ampullary adenocarcinoma (aa) are discordant. this aspect remains poorly studied, with comparably scant research conducted on it. log odds of positive lymph nodes (lodds), a quantitative variable, can continuously and accurately reflect the burden of nodal involvement, which suggested a potential ability to identify aa patients benefiting from postoperative adjuvant chemotherapy (act). therefore, mainly focused issues of act addressed in the study are as follows: 1) the role of act in improving long-term survival for patients with aa after curative resection. 2) the role of lodds in identifying postoperative aa patients benefiting from act. 3) compared with t and n classifications reported previously, the advantage of lodds in identifying act-benefited patients. in this cohort study, a large scale of sample size was conducted by drawing on the collective experience of the national cancer center of china. the patients treated with radiotherapy were excluded to concentrate on the effect of act.


Eligibility criteria:
inclusion criteria: pathologically confirmed aa patients without distant metastasis treated with curative-intent resection exclusion criteria: patients who received neoadjuvant therapy or radiotherapy, as well as those with missing clinical pathological or follow-up information